PACB
Pacific Biosciences of California, Inc.
PACB lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink.
PACB Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Weak | |
| Unavailable |
PACB's revenue is currently stable, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
PACB PE Valuation
PACB has no meaningful PE right now: it lost money over the past year.
PACB Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| -- | |
| Limited | |
| Moderate |
Analysts expect PACB's losses to shrink, with revenue growing.
PACB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2024 | -$1.46 | -$0.19 |
| Q2 2024 | -$1.50 | -$0.15 |
| Q1 2024 | -$1.14 | +$0.25 |
| Q4 2023 | -$1.21 | +$0.19 |
| Q3 2023 | -$1.27 | +$0.07 |
| Q2 2023 | -$1.35 | -$0.43 |
| Q1 2023 | -$1.39 | -$0.58 |
| Q4 2022 | -$1.40 | -$0.51 |
PACB lost $0.40 per share over the past year, a smaller loss than the year before.
PACB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $40.6M | +5.5% |
| Q2 2026 | $39M | -1.9% |
| Q1 2026 | $37.2M | +0.1% |
| Q4 2025 | $44.6M | +14% |
| Q3 2025 | $38.4M | -3.8% |
| Q2 2025 | $39.8M | +10% |
| Q1 2025 | $37.2M | -4.3% |
| Q4 2024 | $39.2M | -33% |
PACB's revenue is recovering but still below its 2023 peak: $41M last quarter, up 5.5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -91% | +9.9 points |
| Q2 2026 | -114% | -1.6 points |
| Q1 2026 | -22% | +1132 points |
| Q4 2025 | -92% | +298 points |
| Q3 2025 | -101% | +59 points |
| Q2 2025 | -113% | +376 points |
| Q1 2025 | -1155% | -945 points |
| Q4 2024 | -390% | -240 points |
PACB's operating margin was −91% last quarter, up 9.9 points from the same quarter a year ago.
PACB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$38.6M | -$20M |
| Q2 2026 | -$37.1M | -$7.2M |
| Q1 2026 | -$47.7M | -$2.3M |
| Q4 2025 | -$19.9M | +$12.3M |
| Q3 2025 | -$18.6M | +$26.1M |
| Q2 2025 | -$29.9M | +$25.8M |
| Q1 2025 | -$45.4M | +$34.1M |
| Q4 2024 | -$32.3M | +$27.3M |
PACB has burned cash in almost every quarter: −$143M over the past year, against −$126M the year before.
PACB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +592K shares |
| 1 year | +3.5% | +10.4M shares |
| 3 years | +22% | +56.2M shares |
| 5 years | +45% | +96.1M shares |
| Available history | +100% | +155M shares |
PACB has 311M diluted shares, up 3.5% from a year ago.
PACB Net Leverage
PACB's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
PACB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 53.2 | Neutral |
| Stochastic | 50.9 | Neutral |
PACB's weekly RSI is 53 (neutral) and its Stochastic is 51 (neutral).
PACB PE vs Healthcare Sector
| Metric | PACB | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
PACB has no meaningful PE right now: it lost money over the past year.
PACB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.15 | 8.4% below |
| 20 week MA | $1.69 | 17% above |
| 50 week MA | $1.67 | 18% above |
| 100 week MA | $1.57 | 25% above |
| 200 week MA | $4.13 | 52% below |
PACB's trend is mixed: it's above three of its five weekly moving averages, and 52% below its 200-week average.
PACB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.24 | $27.1 | +418% |
| 2021 | $27.1 | $21.4 | -21% |
| 2022 | $21.4 | $8.49 | -60% |
| 2023 | $8.49 | $9.81 | +16% |
| 2024 | $9.81 | $1.86 | -81% |
| 2025 | $1.86 | $1.77 | -4.8% |
| 2026 YTD | $1.77 | $1.97 | +11% |
PACB's yearly returns have swung widely, from +418% in 2020 to −81% in 2024. It's up 11% so far in 2026.